CYTARABINE J Code: J9100

Drug & Product Overview

HCPCS Descriptor Injection, cytarabine, 100 mg

HCPCS Added Date January 1, 1986

Manufacturer Multiple Manufacturers

Route of Administration Intrathecal, Intravenous, Subcutaneous

Generic Status Multi-Source; Generic

Dosage Type Single-Dose, Multi-Dose

Dosage Form Injection, Solution

About CYTARABINE

Cytarabine is a medication aligned to the HCPCS J Code: J9100 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intrathecal, intravenous, or subcutaneous routes and manufactured by multiple companies.

According to CMS Drug Use Information: Cytarabine is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 5 of 10 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
25021-0223-20	cytarabine	Sagent Pharmaceuticals	20	2000 MG / 20 ML
25021-0229-05	cytarabine	Sagent Pharmaceuticals	5	100 MG / 5 ML
61703-0155-01	Cytarabine	Hospira, Inc.	20	2000 MG / 20 ML
63323-0120-20	Cytarabine	Fresenius Kabi USA, LLC	20	2000 MG / 20 ML
71288-0109-20	Cytarabine	Meitheal Pharmaceuticals Inc.	20	2000 MG / 20 ML
•••••-••••-•• Log in to view	CYTARABINE
	CYTARABINE
	CYTARABINE

Login to view 5 more NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

CYTARABINE Pricing & Reimbursement

J9100 Private Payer Reimbursement

$0.91 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

CYTARABINE Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 10.52%

Avg. Days to File 6.7days

Avg. Days to Pay 23.3days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9100 claims analytics on FocalPoint →

CYTARABINE CPT Administration Codes

CPT Code	Description
96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Login for More	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) Login for More
96450 Login for More	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture Login for More

Not on the CMS JW / JZ list

CMS does not include Cytarabine (J9100) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J9100. Wastage billing guide →

CYTARABINE Medically Unlikely Edits (MUE)

The most billing units of J9100 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 100 mg.

Practitioner Office & Hospital Outpatient

120 units / day

= 12,000 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

CYTARABINE Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute Lymphocytic Leukemia Acute Non-Lymphocytic Leukemia Acute lymphocytic leukemia Acute non-lymphocytic leukemia Blast Phase Chronic Myelocytic Leukemia Blast Phase of Chronic Myelocytic Leukemia Blast phase of chronic myelocytic leukemia Meningeal Leukemia Meningeal leukemia

Drug Class

Nucleic Acid Synthesis Inhibitors [MoA]Nucleoside Metabolic Inhibitor [EPC]

Frequently Asked Questions

Is there an available Cytarabine billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for CYTARABINE.

Are there any available Cytarabine patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for CYTARABINE.

Where can I find Cytarabine prescribing information?

Our team is still working to identify a prescribing information source for CYTARABINE

Where can I find Cytarabine side effect information?

Our team has not yet identified a source of side effects information for CYTARABINE. Please check back in a few weeks.

Does billing CYTARABINE require JZ/JW wastage modifiers?

CMS does not include CYTARABINE (J9100) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J9100. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.